Sign Up to like & get
recommendations!
1
Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-018-0315-3
Abstract: BackgroundInterferon-induced expression of programmed cell death ligands (PD-L1/PD-L2) may sustain tumour immune-evasion. Patients featuring MET amplification, a genetic lesion driving transformation, may benefit from anti-MET treatment. We explored if MET-targeted therapy interferes with Interferon-γ modulation…
read more here.
Keywords:
treatment;
interferon;
amplified tumours;
induction ligands ... See more keywords